Table 1 Transition probabilities.

From: A cost-effectiveness evaluation of latent tuberculosis infection screening of a migrant population in Malaysia

From

To

(i) Healthy

(ii) Untreated LTBI (treatment Naïve)

(iii) LTBI, taking treatment without AE (%)

(iv) LTBI, taking treatment with AE (%)

(v) Untreated LTBI (previously treated)

(vi) Drug-sensitive TB being treated

(vii) Multidrug resistant TB being treated

(i) Healthy

100%

0%

0

0

0%

0%

0%

(ii) Untreated LTBI (treatment Naïve)

0%

Residual*

0

0

0%

Calculated from LTBI reactivation rates*

Calculated from LTBI reactivation rates*

(iii) LTBI, taking treatment without AE

Calculated from treatment effectiveness

0%

0

0

Calculated from treatment effectiveness

0%

0%

(iv) LTBI, taking treatment with AE

Calculated from treatment effectiveness

0%

0

0

Calculated from treatment effectiveness

0%

0%

(v) Untreated LTBI (previously treated)

0%

0%

0

0

Residual*

Calculated from LTBI reactivation rates*

Calculated from LTBI reactivation rates*

(vi) Drug-sensitive TB being treated

100%

0%

0

0

0%

0%

0%

(vii) Multidrug resistant TB being treated

100%

0%

0

0

0%

0%

0%

  1. AE Adverse event, LTBI Latent tuberculosis infection.
  2. *Values were updated every cycle.